Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 18:15:1484752.
doi: 10.3389/fneur.2024.1484752. eCollection 2024.

Short-term effectiveness and side effects of ketogenic diet for drug-resistant epilepsy in children with genetic epilepsy syndromes

Affiliations

Short-term effectiveness and side effects of ketogenic diet for drug-resistant epilepsy in children with genetic epilepsy syndromes

Osama Y Muthaffar et al. Front Neurol. .

Abstract

Background: Drug-resistant epilepsy (DRE) impacts a significant portion, one-third, of individuals diagnosed with epilepsy. In such cases, exploring non-pharmacological interventions are crucial, with the ketogenic diet (KD) standing out as a valuable option. KD, a high-fat and low-carb dietary approach with roots dating back to the 1920s for managing DRE, triggers the formation of ketone bodies and modifies biochemistry to aid in seizure control. Recent studies have increasingly supported the efficacy of KD in addressing DRE, showcasing positive outcomes. Furthermore, while more research is needed, limited data suggests that KD May also be beneficial for specific genetic epilepsy syndromes (GESs).

Objective: This study aimed to assess the short-term efficacy of KD among pediatric patients diagnosed with GESs.

Materials and methods: This is a multi-center retrospective analysis of pediatric patients with GESs diagnosed using next-generation sequencing. The enrolled patients followed the keto-clinic protocol, and the KD efficacy was evaluated at 3, 6, and 12-month intervals based on seizure control and compliance. The collection instrument included demographic, baseline, and prognostic data. The collected data was coded and analyzed promptly.

Results: We enrolled a cohort of 77 patients with a mean current age of 7.94 ± 3.83 years. The mean age of seizure onset was 15.5 months. Notably, patients experienced seizures at a younger age tended to have less positive response to diet. Overall, 55 patients responded favorably to the diet (71.4%) while 22 patients (28.6%) showed no improvement. Patients with genetic etiology showed a significantly more favorable responses to the dietary intervention. Patients with Lennox-Gastaut syndrome showed the most significant improvement (14/15) followed by patients with Dravet syndrome (6/8), and West syndrome (3/4). The number of used anti-seizure medications also played a significant role in determining their response to the diet. While some patients experienced mild adverse events, the most common being constipation, these occurrences were not serious enough to necessitate discontinuation of the diet.

Conclusion: The study revealed a high improvement rate in seizure control, especially among younger patients and those with later seizure onset. The success of dietary treatment hinges greatly on early intervention and the patient's age. Certain genetic mutations responded favorably to the KD, while efficacy varied among various genetic profiles.

Keywords: children; dietary therapies; drug-resistant epilepsy; epilepsy syndromes; ketogenic diet; seizure.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Algorithm of the keto-clinic protocol adopted in the study’s institutions.
Figure 2
Figure 2
Bar chart of mean seizure control (0–100%) after 3 months of KD, by age group and gender.
Figure 3
Figure 3
Bar chart of mean seizure control (0–100%) after 6 months of KD, by age group and gender.
Figure 4
Figure 4
Bar chart of mean seizure control (0–100%) after 12 months of KD, by age group and gender.

References

    1. Picot MC, Baldy-Moulinier M, Daurès JP, Dujols P, Crespel A. The prevalence of epilepsy and pharmacoresistant epilepsy in adults: a population-based study in a Western European country. Epilepsia. (2008) 49:1230–8. doi: 10.1111/J.1528-1167.2008.01579.X, PMID: - DOI - PubMed
    1. Baeesa SS, Maghrabi YE, Baeesa MS, Jan FM, Jan MM. Publications pattern of clinical epilepsy research in Saudi Arabia. Neurosciences. (2017) 22:255–60. doi: 10.17712/NSJ.2017.4.20170231, PMID: - DOI - PMC - PubMed
    1. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. . Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia. (2010) 51:1069–77. doi: 10.1111/J.1528-1167.2009.02397.X - DOI - PubMed
    1. Liu G, Health A, Slater N, Perkins A. Epilepsy: treatment options. Am Fam Physician. (2017) 96:87–96. PMID: - PubMed
    1. Appleton RE, Freeman A, Cross JH. Diagnosis and management of the epilepsies in children: a summary of the partial update of the 2012 NICE epilepsy guideline. Arch Dis Child. (2012) 97:1073–6. doi: 10.1136/archdischild-2012-302822, PMID: - DOI - PubMed

LinkOut - more resources